Key result
A 62-year-old man developed atrial fibrillation with a rapid ventricular rate of 160-180 beats per minute shortly after his second cycle of mesna-ifosfamide and doxorubicin chemotherapy.
Why the study?
The prevalence of atrial fibrillation in cancer patients receiving radiation or chemotherapy is rising, with alkylating agents and anthracyclines being common offending agents.
Case Report (n=1)
Anthracycline and alkylating agent-based chemotherapy can induce rapid-onset atrial fibrillation, highlighting the need for multidisciplinary cardio-oncology care and careful monitoring.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Its prevalence in cancer patients undergoing treatment with radiation or chemotherapeutic agents has been on the rise. The most common offending agents are alkylating agents and anthracyclines causing various types of arrhythmias, including AF. We report a case of a 62-year-old male who was diagnosed with stage IV pleomorphic rhabdomyosarcoma and was started on chemotherapy with a mesna-ifosfamide and doxorubicin (MAI) regimen. He developed AF with a rapid ventricular rate soon after his second cycle of treatment, which got better with the initiation of beta-blocker therapy. Since low blood counts, including low platelet levels, are expected in patients with chemotherapy, the continual use of anticoagulation therapy varies on a case-to-case basis.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2023) conducted a case report in Pleomorphic rhabdomyosarcoma (n=1). Mesna-ifosfamide and doxorubicin (MAI) chemotherapy was evaluated on Development of atrial fibrillation with rapid ventricular response. A 62-year-old man developed atrial fibrillation with a rapid ventricular rate of 160-180 beats per minute shortly after his second cycle of mesna-ifosfamide and doxorubicin chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: